ClinicalTrials.gg
RecruitingNCT03204357Updated Nov 21, 2024

Fresh Autologous Whole Blood Transfusion After Cardiopulmonary Bypass

An interventional study of Fresh Autologous whole Blood and Standard of Care Expectant management of bleeding in Cardiac Disease and Bleeding Postoperative, sponsored by University of Colorado, Denver. Recruiting at 1 site in United States. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2024-11-21.

Sponsored by University of Colorado, Denver · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2025, 1 year 3 months ago, but the record still lists the study as recruiting.
  • Started Jan 2022; still recruiting 4 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 646 studies in Heart Diseases with a site in United States — 92 open to participants now, 131 under way, 5 of them phase 3. Heart Diseases · United States.

Planned enrollment
285th of 430
70 · median 161
Started
2022
with 13 others
No phase
244 of 646
40 open now
Primary completion
2025-08
later than 16 of 128 live
Registered
414th of 646
by date

Among the 646 studies in Heart Diseases with a site in United States, this one is the 285th largest by planned enrollment of the 430 interventional ones that give a count, is one of 14 that started in 2022, is one of 244 with no phase, reaches primary completion later than 16 of the 128 other live ones, and was the 414th registered.

Heart Diseases

2,135 studies on the registry are indexed under Heart Diseases; 250 are open to participants now.

Browse Heart Diseases studies →

Open to participants now

92 of the 646 studies in Heart Diseases with a site in United States are open now. Recruiting first, the newest first:

87 more — sign in →

All 92 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 182 Heart Diseases studies recruiting now, 128 (70%) set no upper age limit and 22 (12%) stop at 75 or younger; 33 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 646 studies in Heart Diseases with a site in United States, or all of them as a file.
02

Study summary

Autologous blood transfused at the end of cardiopulmonary bypass will reduce total blood loss 24 hours after surgery and improve mitochondrial oxygen delivery measured by plasma succinate levels.

The study design is a prospective randomized interventional trial of transfusion of fresh autologous whole blood versus standard of care expectant management of bleeding during elective cardiac surgery.

Read the detailed description

Cardiac surgery carries a significant risk of bleeding requiring transfusion of stored blood products and blood transfusion associated with cardiac surgery consumes 20% of the blood supply worldwide. Although transfusion may be life-saving, significant risks of complications such as lung injury or even an increase in mortality are associated with transfusion. Decreasing transfusion requirements during cardiac surgery has the potential to reduce the rate of complications, improve patient outcomes, and reduce cost resulting in increased value for both the patient and the health system as a whole. Collection of autologous blood before cardiopulmonary bypass (CPB) for transfusion after CPB has been shown to be both safe and effective for reducing blood loss during cardiac surgery, but this intervention has not been targeted to a patient population at high risk for bleeding and transfusion. Fresh whole blood has the capacity to restore coagulation system function during profound coagulopathy in a trauma setting or following massive transfusion by an unknown mechanism. One unit of fresh whole blood is able to restore clotting function equivalent to that achieved by 10 units of pooled platelets. Autologous whole blood collection prior to CPB for transfusion post-operatively has been shown to improve coagulation and decrease clot lysis but is not routinely performed because 90% to 95% of patients do not have extensive blood loss and subsequent coagulopathy. Coupling accurate pre-operative bleeding risk prediction with autologous fresh whole blood collection for transfusion after CPB would target an established, low cost, low risk intervention to an at risk patient population who may experience significant benefit.

03

Conditions studied

  • Cardiac Disease
  • Bleeding Postoperative

Keywords

  • Cardiac surgery
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult subjects aged 18 to 90
  2. Able to provide
  3. Willing to accept autologous or allogenic blood transfusion
  4. Scheduled for elective cardiac surgery with cardiopulmonary bypass

Exclusion criteria

Exclusion Criteria:

  1. Pre-operative administration of allogenic blood bank products in the previous 3 months
  2. Hemodynamically unstable defined as a systolic blood pressure less than 90 mmHg with a heart rate greater 100 or requiring intravenous vasopressor medications
  3. Significant active infection or sepsis defined by positive blood culture or positive wound culture
  4. less than 7 g/dl
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    Fresh Autologous whole blood transfusion

    The experimental group will have 15% of the estimated blood volume of autologous blood collected. This transfusion will be given at the end of the procedure.

    Other: Fresh Autologous whole Blood

  • Active comparator
    Standard of Care Expectant Management of bleeding

    the control group that will receive the standard of care expectant management of bleeding and transfusion of allogenic banked blood products

    Other: Standard of Care Expectant management of bleeding

Interventions

  • OtherFresh Autologous whole Blood

    Subjects randomized this arm will receive fresh autologous whole blood

  • OtherStandard of Care Expectant management of bleeding

    the control group that will receive the standard of care expectant management of bleeding and transfusion of allogenic banked blood products

06

What researchers measure

Primary outcomes

  1. Estimated Blood Loss

    Blood loss is estimated as a percent of total estimated blood volume in the first 24 hours after cardiac surgery.

    Time frame: Within 24 hours after surgery

Secondary outcomes

  1. Number of allogenic transfusions given

    Allogenic blood product transfusion requirements

    Time frame: 31 days

  2. Severity of peri-operative stroke

    The severity of peri-operative stroke will be measured by the National institute of health stroke scale

    Time frame: 31 days

  3. Incident of peri-operative stroke

    The incident of peri-operative stroke will be measured by the National institute of health stroke scale

    Time frame: 31 days

  4. Development of Post-operative delirium

    Measured by Confusion Assessment Method - Intensive Care Unit

    Time frame: 31 days

  5. Development of Myocardial Infarction

    As measured by physiological parameters

    Time frame: 31 days

  6. Development of Heart failure

    As measured by physiological parameters

    Time frame: 31 days

  7. Detection of New Onset Atrial fibrillation

    As measured by an electrocardiogram

    Time frame: 31 days

  8. Development of Lung injury

    Measured by a Pa02/Fi02 ratio

    Time frame: 31 days

  9. Time to extubation

    Time from when the breathing tube was placed to the time when the breathing tube is removed

    Time frame: 31 days

  10. Development of Acute Kidney Injury

    As measured by abnormal lab values

    Time frame: 31 days

  11. Initiation of renal replacement therapy

    Time to start of renal replacement therapy

    Time frame: 31 days

  12. ICU length of stay

    This will be measured by the number of days in ICU

    Time frame: 31 days

  13. Evaluation of Vasopressor requirements (1)

    Measurement of the amount of vasopressors given

    Time frame: 31 days

  14. Evaluation of Vasopressor requirements (2)

    Measurement of the types of vasopressors given

    Time frame: 31 days

  15. Change in endothelial function measured by flow mediated dilation of the brachial artery

    Measurement of brachial artery dilation in response to flow by ultrasonography

    Time frame: 24 hours after surgery

07

Study locations

1 of 1 sites recruiting
  • University of Colorado Hospital
    Aurora, Colorado 80045, United States
    Recruiting
    • Nathan Clendenen, MD MS · Contact
    • Nathan J Clendenen, MD MS · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2022 (actual). Primary completion is estimated for Aug 2025, 43 months after the start.

Of 264 non-industry interventional studies with no phase under Heart Diseases, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 51. This study's planned 43 months is above that.

Counting every sponsor, half of 337 studies reached it within 25 months; a quarter within 11 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2017
First posted
Jul 2, 2017
StartActual
Jan 24, 2022
Primary completionEst.
Aug 2025
CompletionEst.
Sep 2026
Last update
Nov 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03204357
Responsible party
Sponsor
First posted
Jul 2, 2017
Start date
Jan 24, 2022
Primary completion
Aug 2025 (estimated)
Completion
Sep 2026 (estimated)
Last update
Nov 21, 2024

Study contacts

Nathan J Clendenen, M.D.
Contact
nathan.clendenen@cuanschutz.edu
720-848-6709
Nick Naughton, B.A
Contact
nick.naughton@cuanschutz.edu
720-848-6709
Nathan Clendenen, M.D.
principal investigator · University of Colorado - School of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion